<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03831750</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00082125; Pro00079377</org_study_id>
    <nct_id>NCT03831750</nct_id>
  </id_info>
  <brief_title>Assessing the Effectiveness of a Stress Reduction Intervention in Inflammatory Bowel Disease (IBD)</brief_title>
  <official_title>Assessing the Effectiveness of a Stress Reduction Intervention in Inflammatory Bowel Disease (IBD): a Prospective Randomized Controlled Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have designed a guided, online, tri-component, stress reduction
      intervention for participants with inflammatory bowel diseases. In two blinded randomized
      controlled trials (categorized by disease subtype: UC and CD), the investigators will assess
      the impact of an online 3-month stress reduction intervention on perceived stress level
      (primary outcome) and the following (secondary outcomes): anxiety, depression, IBD disease
      activity (e.g., changes in CRP, fecal calprotectin, medication, hospitalization, or surgery),
      serum inflammatory markers, serum and salivary markers of stress, stress-resilience, and
      health- related quality of life. Participant satisfaction and adherence to the intervention
      will be evaluated.relative to the control group plus standard care.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Sealed envelopes</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Perceived stress</measure>
    <time_frame>3 months</time_frame>
    <description>Change in a participant's stress index from baseline to end of study using the Perceived Stress Scale (PSS)-10 item. Summed scores range from 0-40 where lower scores are associated with less perceived stress compared to higher scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mental health</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline to end of study using the Hospital and Anxiety Depression Scale (HADS). Summed scores (range: 0-21) are separate for anxiety and depression; lower scores are assocated with less perceived anxiety or depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline to end of study using the Short IBD Quality of Life Questionnaire (SIBDQ). Scores (range 1-7) for the 7 questions are summed where higher scores related to a higher perceived health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation and stress</measure>
    <time_frame>3 months</time_frame>
    <description>Changes from baseline to end of study for 6 serum pro- and anti-inflammatory immune biomarkers relevant to IBD (IL-10, IL-12, IL-1ß, IL-4, IL-6, TNF-α) and markers of stress, including CABS1 and cortisol, with the Connor Davidson Resilience Scale (score range: 0 to 100). Higher scores with the Connor Davidson Resilience Scare are indicative of greater stress resiliency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBD levels of activity</measure>
    <time_frame>3 months</time_frame>
    <description>Changes from baseline to end of study for fecal calprotectin and Partial Mayo Score (score range 0-9; lower scores mean less or no disease activity) or the Harvey Bradshaw Index (HBI) (range=0-16+; where lower scores indicate less or no disease activity).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Remission</condition>
  <condition>Perceived Stress</condition>
  <arm_group>
    <arm_group_label>Stress Reduction Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the standard of care for IBD and training and access to an online stress reduction intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive the standard of care for IBD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stress Reduction Intervention</intervention_name>
    <description>The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.</description>
    <arm_group_label>Stress Reduction Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (RCT):

          -  Adults (≥18 years)

          -  with IBD in remission (UC - partial Mayo &lt;2 and fecal calprotectin &lt;250 μg/g; CD
             regular HBI &lt;5 or CRP &lt;8)

          -  on stable therapy for the past 3 months

          -  the last flare &lt;24 months prior to enrollment

          -  PSS-10 score ≥ 7 at time of screening

        Inclusion Criteria (Substudy):

          -  Adults (≥18 years)

          -  IBD

          -  on stable therapy for the past 3 months.

        Exclusion Criteria (RCT or Substudy):

          -  Major medical co-morbidity

          -  Steroid use in past 3 months

          -  Clostridium difficile infection in the last 3 months

          -  Unstable dose of psychiatric medications for the last 3 months

          -  Inability to provide informed written consent

          -  Severe psychiatric disorders (HADS scores &gt;10 or suicidal ideation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Peerani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Puneeta Tandon, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ritz T, Rosenfield D, St Laurent CD, Trueba AF, Werchan CA, Vogel PD, Auchus RJ, Reyes-Serratos E, Befus AD. A novel biomarker associated with distress in humans: calcium-binding protein, spermatid-specific 1 (CABS1). Am J Physiol Regul Integr Comp Physiol. 2017 Jun 1;312(6):R1004-R1016. doi: 10.1152/ajpregu.00393.2016. Epub 2017 Apr 5.</citation>
    <PMID>28381457</PMID>
  </reference>
  <reference>
    <citation>Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010 Sep;105(9):1994-2002. doi: 10.1038/ajg.2010.140. Epub 2010 Apr 6.</citation>
    <PMID>20372115</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>remission</keyword>
  <keyword>perceived stress</keyword>
  <keyword>fecal calprotectin</keyword>
  <keyword>salivary stress biomarker</keyword>
  <keyword>psychological stress</keyword>
  <keyword>stress reduction</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>Inflammatory bowel diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

